onc Videos

Videos

Conference Coverage

Trastuzumab, Pertuzumab, and Docetaxel Remains Standard of Care for Older Patients With HER2-Positive Metastatic Breast Cancer

01/03/2024

Featuring Akihiko Shimomura, MD

Featuring Akihiko Shimomura, MD ...

Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...

Akihiko Shimomura, MD, discussed...

01/03/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Featuring Douglas Tremblay, MD

Featuring Douglas Tremblay, MD ...

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Use of a 12-Gene DCIS Score to Guide Radiotherapy Decisions for Patients With Ductal Carcinoma in Situ

01/03/2024

Featuring Seema Khan, MD

Seema Khan, MD, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.

Seema Khan, MD, discussed 5-year...

01/03/2024

Oncology

Conference Coverage

Individualization of Therapies for Patients With HR-Positive, HER2-Negative Breast Cancer

01/03/2024

Featuring Rick Baehner, MD

Rick Baehner, MD, discussed results from the phase 3 ADAPTcycle trial.

Rick Baehner, MD, discussed...

01/03/2024

Oncology

Conference Coverage

Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML

01/03/2024

Featuring Talha Badar, MD

At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Maternal and Neonatal Safety of Taxane Chemotherapy During Pregnancy for the Treatment of Breast Cancer

12/28/2023

Featuring Ana Ferrigno, MD

Ana Ferrigno, MD, discussed results from an international cohort study which demonstrated that the use of taxane-containing chemotherapy during pregnancy does not increase the risk of obstetric and neonatal complications.

Ana Ferrigno, MD, discussed...

12/28/2023

Oncology

Conference Coverage

Loco-Regional Irradiation for Patients With Biopsy-Proven Axillary Node Involvement Who Become Node-Negative After Neoadjuvant Chemotherapy

12/28/2023

Featuring Eleftherios Mamounas, MD

Featuring Eleftherios Mamounas, MD ...

Eleftherios Mamounas, MD, discussed primary results from the NRG Oncology/NSABP B-51/RTOG 1304 study.

Eleftherios Mamounas, MD,...

12/28/2023

Oncology

Conference Coverage

Use of a Structured, Individualized Exercise Program for Patients With Metastatic Breast Cancer

12/28/2023

Featuring Anouk Hiensch, PhD

Anouk Hiensch, PhD, discussed results from the PREFERABLE-EFFECT study, which demonstrated that starting a structured, individualized exercise intervention during palliative treatment for metastatic breast cancer decreased fatigue and...

Anouk Hiensch, PhD, discussed...

12/28/2023

Oncology

Shernan G Holtan, MD, University of Minnesota

Conference Coverage

Selective Oral AURKA Inhibitor for Graft-Versus-Host Disease and Relapse Prophylaxis Following Allogeneic HCT

12/21/2023

Featuring Shernan G Holtan, MD

Featuring Shernan G Holtan, MD ...

At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...

At the 2023 ASH Annual Meeting,...

12/21/2023

Oncology

Ryan Lynch, MD, Fred Hutch Cancer Center

Videos

Evaluating Early Complete Responses of Mosunetuzumab Monotherapy for Patients With Previously Untreated Follicular Lymphoma and MZL

12/21/2023

Featuring Ryan Lynch, MD

At the 65th ASH Annual Meeting, Ryan C Lynch, MD, presented data on the high complete response rates of mosunetuzumab in previously untreated patients with follicular lymphoma and marginal zone lymphoma and only low-grade cytokine release...

At the 65th ASH Annual Meeting,...

12/21/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology